Patent · US Active

RET kinase inhibitors

US11697647B2 · kind B2 · utility

1Cited by
0References
25Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 5, 2021
Grant dateJul 11, 2023
Priority date—
Expiry dateNov 5, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D417/14
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

Disclosed herein are compounds of formula I: or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.